November 5, 2019
SCOR Global Life has made a strategic investment in BioSerenity, a French medical solutions company that aims to optimize the patient pathways in several chronic diseases through the design of connected devices, end-t
This publication presents some global information on kidney diseases, the definitions and basic notions, protective treatments, renal replacement therapies, disease progression information as well as proposed underwri
October 28, 2019
In order to achieve the objectives of the “Quantum Leap” strategic plan, SCOR Global Life evolves its organisation and announces promotions in its Global Markets team.
First Nine Months 2019 Results
SOLEM supports our clients throughout the world to assess risks, including a dedicated Claims management section.
A.M. Best has decided to affirm SCOR’s Financial Strength Rating of ‘A+ (Superior)’ and its Long-Term Issuer Credit Ratings of ‘aa-’.
SCOR was named “North America Reinsurer of the Year” by Reactions at its North America Awards ceremony in New York on September 26, 2019.
SCOR has been informed of the decision by Standard & Poor’s (S&P) to affirm the financial strength rating for the Group and its main subsidiaries at “AA-”, with a “stable outlook”, and to maintain the counterp
At its annual Investor Day in Paris, SCOR presents its new strategic plan, “Quantum Leap”.
Investor Day 2019: presentation
The growing use of economic-value-based metrics will greatly benefit longstanding reinsurers, writes Denis Kessler, Chairman and CEO of SCOR, for the CEO Forum
